STOCK TITAN
  1. Home
  2. Sec-filings
  3. POM
  4. [6-K] POMDOCTOR Ltd Current Report (Foreign Issuer)

POMDOCTOR (NASDAQ: POM) implements 1-for-18 reverse ADS split in June 2026

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

POMDOCTOR LIMITED is implementing an ADS ratio change that will take effect on June 22, 2026, U.S. Eastern Time. Each American depositary share will change from representing one-sixth of a Class A ordinary share to representing three Class A ordinary shares.

For ADS holders, this functions as a one-for-eighteen reverse ADS split: every eighteen existing ADSs will be automatically exchanged for one new ADS, with no action required by holders. No changes are being made to the underlying Class A ordinary shares.

POMDOCTOR’s ADSs are expected to begin trading on Nasdaq on a post-reverse ADS split basis under the same ticker “POM” on the effective date. The company states that the ADS trading price is expected to increase proportionally, but it gives no assurance that the post-change price will equal or exceed eighteen times the prior price.

Positive

  • None.

Negative

  • None.
Current ADS ratio 1 ADS = 1/6 Class A share Prior to June 22, 2026
New ADS ratio 1 ADS = 3 Class A shares Effective June 22, 2026
Reverse ADS split 1-for-18 Effect for ADS holders
Effective date June 22, 2026 ADS ratio change effective U.S. Eastern Time
Ticker symbol POM ADSs continue trading on Nasdaq under same ticker
New CUSIP 73181R207 ADS CUSIP after ratio change
American depositary shares financial
"the ratio change of its American depositary shares (the “ADSs”) to Class A ordinary shares"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
reverse ADS split financial
"the ADS Ratio Change will have the same effect as a one-for-eighteen reverse ADS split"
A reverse ADS split is a corporate action that combines multiple American Depositary Shares (ADS) into a smaller number of ADS, so each new ADS represents more underlying ordinary shares and the price per ADS rises proportionally. Think of merging several small coins into one bigger coin: your total value stays the same, but the share count and per‑share price change, which can affect trading liquidity, index inclusion, and investor perception of the stock.
Depositary financial
"new ADSs being issued by Citibank, N.A., the depositary bank for the Company’s ADS program (the “Depositary”)"
A depositary is a financial institution that holds and safeguards financial assets, such as stocks or bonds, on behalf of investors. It ensures that ownership records are accurate and that transactions are processed securely. For investors, a depositary provides a trustworthy way to manage their investments, similar to a secure vault that keeps valuables safe and organized.
Direct Registration System financial
"holders of ADSs in the Direct Registration System and in The Depository Trust Company will have their ADSs automatically exchanged"
A direct registration system allows investors to register their ownership of securities directly with the issuing company or its transfer agent, rather than holding shares through a broker or intermediary. This setup gives investors more control over their holdings and simplifies the process of buying or selling shares. It is important because it can reduce costs, increase transparency, and provide a clearer record of ownership.
forward-looking statements regulatory
"Certain statements in this announcement are forward-looking statements."
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 6-K

 

 

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of June 2026

 

Commission file number: 001-42749

 

 

 

POMDOCTOR LIMITED

 

 

 

Yongxu Industrial Park

No.19-23 Hejing Road, Dongsha Street

Liwan District, Guangzhou 510000

People’s Republic of China

(Address of principal executive offices)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒     Form 40-F ☐

 

 

 

 

 

EXHIBIT INDEX

 

Exhibit No.   Description
99.1   Press Release—POMDOCTOR LIMITED Announces ADS Ratio Change to Be Effective on June 22, 2026

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  POMDOCTOR LIMITED
   
  /s/ Zhenyang Shi
  Zhenyang Shi
  Chairman and Chief Executive Officer

 

Date: June 17, 2026

 

2

 

Exhibit 99.1

 

POMDOCTOR LIMITED Announces ADS Ratio Change to Be Effective on June 22, 2026

 

GUANGZHOU, China, June 17, 2026 /PRNewswire/ - POMDOCTOR LIMITED (the “Company”) (NASDAQ: POM), a leading online medical services platform for chronic diseases in China, today announced that, as previously announced on May 28, 2026, the ratio change of its American depositary shares (the “ADSs”) to Class A ordinary shares from the current ratio of one (1) ADS representing one-sixth (1/6) Class A ordinary share to a new ratio of one (1) ADS representing three (3) Class A ordinary shares (the “ADS Ratio Change”) will become effective on June 22, 2026, U.S. Eastern Time (the “Effective Date”).

 

For the Company’s ADS holders, the ADS Ratio Change will have the same effect as a one-for-eighteen reverse ADS split. There will be no change to the Company’s Class A ordinary shares. On the Effective Date, holders of ADSs in the Direct Registration System and in The Depository Trust Company will have their ADSs automatically exchanged and need not take any action. The exchange of every eighteen (18) then-held existing ADSs for one (1) new ADS will occur automatically on the Effective Date, with the then-held ADSs being cancelled and new ADSs being issued by Citibank, N.A., the depositary bank for the Company’s ADS program (the “Depositary”).

 

The Company’s ADSs are expected to begin trading on the Nasdaq Stock Market on a post-reverse ADS split basis under the same ticker symbol “POM” at the market opening on the Effective Date. The new CUSIP number for the Company’s ADSs following the ADS Ratio Change will be 73181R207.

 

No fractional new ADSs will be issued in connection with the ADS Ratio Change. Instead, fractional entitlements to new ADSs will be aggregated and sold by the Depositary and the net cash proceeds from the sale of the fractional ADS entitlements will be distributed to the applicable ADS holders by the Depositary, in each case in accordance with the Depositary’s then-current procedures and practices and after any deductions as provided in the deposit agreement between the Company and the Depositary for the ADSs.

 

As a result of the ADS Ratio Change, the ADS trading price is expected to increase proportionally, although the Company can give no assurance that the ADS trading price after the ADS Ratio Change will be equal to or greater than eighteen times the ADS trading price before the change.

 

About POMDOCTOR LIMITED

 

POMDOCTOR LIMITED is a leading online medical services platform for chronic diseases in China, ranking sixth on China’s Internet hospital market based on the number of contracted doctors in 2022, according to Frost & Sullivan. Focusing on chronic disease management and pharmaceutical services, the Company offers a one-stop platform for medical services, organically connecting patients with doctors and pharmaceutical products. The Company’s operations primarily include Internet hospital and pharmaceutical supply chain, connecting users, pharmacies, suppliers, medical professionals, and other healthcare participants. Through this model, POMDOCTOR aims to enhance the efficiency and transparency of the healthcare value chain. The Company’s mission is to provide effective prevention and treatment solutions to alleviate patients’ sufferings from illnesses. Its vision is to become the most trustworthy medical and healthcare services platform. For more information, please visit the Company’s website: http://ir.7shiliu.com.

 

Forward-Looking Statements

 

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s filings with the SEC.

 

For more information, please contact:

 

POMDOCTOR LIMITED 

Investor Relations Department
Email: ir@7lk.com

 

Ascent Investor Relations LLC 

Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com

Source: View Original Filing on SEC EDGAR

FAQ

What ADS ratio change did POMDOCTOR (POM) announce on its Form 6-K?

POMDOCTOR is changing each ADS from representing one-sixth of a Class A ordinary share to representing three Class A ordinary shares. For holders, this has the same effect as a one-for-eighteen reverse ADS split.

When will POMDOCTOR’s new ADS ratio become effective?

The ADS ratio change becomes effective on June 22, 2026, U.S. Eastern Time. On that date, existing ADSs will be automatically exchanged for new ADSs, and trading will begin on a post-reverse ADS split basis on Nasdaq.

How will POMDOCTOR’s ADS reverse split work for current ADS holders?

Every eighteen then-held existing ADSs will be automatically exchanged for one new ADS, with the old ADSs cancelled and new ADSs issued by Citibank, N.A. Holders in DRS and DTC do not need to take any action for this exchange.

Will POMDOCTOR issue fractional ADSs after the ratio change?

No fractional new ADSs will be issued. Fractional entitlements will be aggregated and sold by the depositary, and net cash proceeds from those sales will be distributed to applicable ADS holders, after deductions allowed under the deposit agreement.

Does the ADS ratio change affect POMDOCTOR’s Class A ordinary shares?

The company states there will be no change to POMDOCTOR’s Class A ordinary shares. The adjustment applies only to the ratio between ADSs and Class A ordinary shares, not to the underlying ordinary share structure itself.

How might POMDOCTOR’s ADS trading price be affected by the ratio change?

POMDOCTOR expects the ADS trading price to increase proportionally following the one-for-eighteen reverse ADS split. However, it explicitly notes there is no assurance the post-change price will be equal to or greater than eighteen times the prior ADS price.

Filing Exhibits & Attachments

1 document

Press Releases